Assessing Denali Therapeutics (DNLI) Valuation After Positive Hunter Syndrome Trial Data And FDA Priority Review [Yahoo! Finance]
Denali Therapeutics Inc. (DNLI)
Last denali therapeutics inc. earnings: 8/6 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.denalitherapeutics.com
Company Research
Source: Yahoo! Finance
New England Journal of Medicine, alongside ongoing FDA Priority Review and accelerated approval efforts. See our latest analysis for Denali Therapeutics. Despite the recent clinical momentum, Denali Therapeutics' share price return tells a mixed story, with a 7 day gain of 2.67%, a 30 day share price return decline of 13.92%, a 1 year total shareholder return decline of 20.24%, and a 5 year total shareholder return decline of 77.76%. This shows that longer term holders have faced significant volatility and suggests that recent enthusiasm around tividenofusp alfa is building from a weakened base. If this kind of early stage biotech story interests you, it can be useful to widen your watchlist to other specialised healthcare stocks that are also trying to turn clinical milestones into long term value. With the stock at US$16.95, trading at a sizable discount to the average analyst price target and sitting on years of weak total returns, you have to ask: is this a mispriced clini
Show less
Read more
Impact Snapshot
Event Time:
DNLI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DNLI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DNLI alerts
High impacting Denali Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
DNLI
News
- Denali Therapeutics (NASDAQ:DNLI) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.MarketBeat
- Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up [Yahoo! Finance]Yahoo! Finance
- Denali Therapeutics (NASDAQ:DNLI) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.MarketBeat
- Denali Therapeutics (NASDAQ:DNLI) was given a new $25.00 price target on by analysts at UBS Group AG.MarketBeat
- Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter SyndromeGlobeNewswire
DNLI
Earnings
- 11/6/25 - Beat
DNLI
Sec Filings
- 1/8/26 - Form 4
- 1/8/26 - Form 4
- 1/6/26 - Form 144
- DNLI's page on the SEC website